Generics (Jeneriku) and the Cost Question

Generic medicine in Japan is the lower-priced twin of a brand drug, sold after the original patent period ends.¹ For repeat prescriptions it is often the simplest way to cut the drug bill without changing the treatment, because the pharmacist will ask you to choose at the counter.

Confirm current details with official sources

Procedures, fees, and requirements can change. Confirm current details at the Ministry of Health, Labour and Welfare site. This article is general information, not medical advice; for diagnosis, treatment, or substitution decisions, consult a licensed physician.

Overview

A generic contains the same active ingredient as the original drug and, as a general rule, the same efficacy, effect, dosage and administration.¹ The formal name is 後発医薬品 (kouhatsu iyakuhin, "generic drug"); the everyday word is ジェネリック医薬品 (jenerikku iyakuhin, "generic drug"), shortened to jeneriku.²

Generics reach the market once the original maker's patent and re-evaluation period expire and other makers produce the same ingredient from the published patent information.¹ Approval requires equivalence testing against the original on test procedures and acceptance criteria, stability, and bioequivalence studies.¹

The price gap exists because the generic maker skips the original clinical-trial research and development cost, so the National Health Insurance (NHI) price is set well below the brand.¹ MHLW frames wider generic use as a way to hold care quality while curbing patient burden and insurance spending.²

Why Japan pushes generics

Japan's universal coverage keeps counter payments low per visit, but an aging population keeps total medical spending rising. Generics are the government's main cost-management lever inside the drug bill, promoted through targets, prescribing rules, and pharmacy incentives rather than compulsion.¹

The 2013 roadmap and the 80 percent target

MHLW issued a safe-use action program in 2007 and a further-promotion roadmap in April 2013 with quantity-share targets.² The June 2015 cabinet decision set 70% by 2017 and 80% by September 2020, to be reached as early as possible.¹

Volume share here means generic quantity against the sum of generics plus brand drugs that have a generic equivalent.³ On that definition, MHLW states that quantity share among drugs where a generic exists stands at about eight in ten (as of 2026-09; confirm current figures with the Ministry of Health, Labour and Welfare), making generics a core base of care.²

The hub separately cites 88.8% in the September drug-price survey of Reiwa 7 (as of 2025-09).² The 2021 Basic Policy restated the goal as over 80% in every prefecture by end of FY2023.⁴

The 2024 roadmap revision

Quality and supply weaknesses in the generic industry surfaced after 2021, including manufacturing violations and large recalls, shaking prescriber and patient confidence. MHLW therefore revised the 2013 roadmap in September 2024 into a roadmap for appropriate generic use grounded in stable supply.⁵²

The revised main target is quantity share of 80% or more in every prefecture by end of FY2029 (as of 2024-09-30; confirm current figures with the Ministry of Health, Labour and Welfare).⁵² A secondary value-share target of 65% or more by end of FY2029 sits alongside it (as of 2024-09-30).² Biosimilar targets were split into a separate policy track and are outside this article's scope.²

Brand or generic at the pharmacy counter

Take the 処方箋 (shohousen, "prescription form") from the clinic to any insurance 薬局 (yakkyoku, "dispensing pharmacy"). The brand-or-generic question happens there, not at the doctor's desk, in the standard case.¹

The chart above shows the counter decision. A blocked prescription goes straight to the brand, while a standard one pauses for the patient's choice.¹

What the pharmacist asks and what consent means

The common rule is generic-name prescribing: the doctor writes the active-ingredient name rather than a brand name.¹ Unless the doctor has signed to block change, the pharmacy is encouraged to brief the patient and dispense a generic with the patient's consent.¹

Incentives exist so pharmacies proactively offer the switch.¹ In practice the question sounds like "brand or generic?", and either answer is accepted for that fill.

A doctor who wants the brand signs the prescription to require it and block substitution.¹ The pharmacist then dispenses as written and does not offer the switch for that fill.

How the saving works

A newly listed generic is priced at 50% of the original drug price, or 40% for oral drugs when more than 10 brands are proposed at once.¹³ That listing arithmetic is where the familiar saving band comes from: about half off at the 50% rule, about six-tenths off at the 40% rule, and about three-tenths off at the 70% biosimilar rule used for comparison.¹³

In practice NHI reimbursement prices for generics sit significantly below the original, generally at 50% or less.¹ Later NHI revisions track actual market prices, so where several generics compete the listed price falls further and grouped generics converge to a single price per band.¹

Item	Amount	As of	Notes
First generic vs original, base rule	50% of original	standing rule13	NHI list price at first listing
First generic, oral, 10+ brands proposed	40% of original	standing rule13	Oral-drug exception
First biosimilar vs original, for comparison	70% of original	standing rule13	Separate track, not a generic

The table prices are NHI list mechanics. Confirm current figures with the Ministry of Health, Labour and Welfare before budgeting a course.

Answer generic for repeat courses to bank the percentage every refill

The percentage gap repeats on every fill, so chronic courses accumulate the saving while one-off courses barely move the yen total.¹

The saving applies to the drug-price component only. Dispensing fees and the clinic's consultation charges stay the same either way, so a short or cheap course saves little in absolute yen even when the percentage gap is wide.¹

When the brand stays

The brand stays in two situations: the doctor blocks the switch on the prescription, or the prescription's wording plus the pharmacy's stock leaves no generic to offer. Both are normal and neither needs justification from the patient.¹

Physician-blocked substitution

A signed block means the pharmacist must dispense the brand as written.¹ The patient is not offered the switch for that fill, and asking again at the same counter does not override the instruction.

A block can cover a single course or repeat while the clinical reason lasts. Any question about why it was blocked goes to the prescribing doctor, not the pharmacy.¹

Narrow-therapeutic-index and allergy cases in general terms

In rare cases the brand is medically warranted as a category. Certain narrow-therapeutic-index drugs, where small blood-level differences matter in clinical judgment, and specific excipient or allergy cases fall into this group.¹

The decision sits with the prescribing physician, who blocks substitution on the prescription when it applies (limitation: this article names no products by design; any substitution question for an ongoing course goes to the prescribing physician and the dispensing pharmacist).¹ This article recommends no specific product and warns against none.

Good to know

The saving is on the drug price, not the whole receipt

The percentage gap can look dramatic while the receipt barely moves. Dispensing and consultation charges stay fixed, so a three-day course of a cheap drug saves tens of yen while a monthly chronic course saves real money.¹

Compare the drug-price line, not the receipt total, when judging whether the switch mattered.

Saying generic once does not lock every future refill

The choice is per dispensing, not a one-time account setting.¹ Each refill follows its own prescription wording and the pharmacy's current stock, so the pharmacist may ask again or dispense differently next time.

If you want the same answer every visit, say so at each counter visit. No record carries the preference forward against a newly blocked prescription.¹

Supply interruptions can push you back to the brand temporarily

A generic used last time can be out of stock this time. MHLW rebuilt the 2024 roadmap around stable supply after industry quality and shortage problems, and pharmacies dispense what is available with an explanation (as of 2024-09-30).²⁵

Treat a temporary return to the brand as logistics, not a verdict on generics. Stock is facility-specific and changes between fills.

This article describes cost mechanics and access paths only. It gives no medical advice and recommends no specific product; for any health concern or substitution question, consult a licensed physician or the dispensing pharmacist.

See also

• How Japan's Universal-Coverage System Works
• Clinic vs. Hospital: The Two-Tier System
• What Insurance Doesn't Cover
• What to Bring to a Doctor's Visit
• How Japanese Pharmacies Work
• The Medication Record Book (Okusuri Techo)

References

Footnotes

1. Health and Global Policy Institute (HGPI), Japan Health Policy NOW. "6.2 Generic Drugs" (definition, bioequivalence, MHLW position, prescribing/dispensing, pricing rules). https://japanhpn.org/en/section-6-2/ ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰ ↩¹¹ ↩¹² ↩¹³ ↩¹⁴ ↩¹⁵ ↩¹⁶ ↩¹⁷ ↩¹⁸ ↩¹⁹ ↩²⁰ ↩²¹ ↩²² ↩²³ ↩²⁴ ↩²⁵ ↩²⁶ ↩²⁷ ↩²⁸ ↩²⁹ ↩³⁰

2. Ministry of Health, Labour and Welfare (MHLW). 「後発医薬品（ジェネリック医薬品）及びバイオ後続品（バイオシミラー）の使用促進について」 (Generic and biosimilar promotion hub). https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/iryou/kouhatu-iyaku/index.html ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶ ↩⁷ ↩⁸ ↩⁹ ↩¹⁰

3. MHLW / PMDA. "Update of Drug Pricing System in Japan" (NHI listing rules: first generic at 50%, 40% if 10+ oral brands; 80% by Sept 2020 target slide). https://www.pmda.go.jp/files/000221888.pdf ↩ ↩² ↩³ ↩⁴ ↩⁵ ↩⁶

4. Suzuki T et al. "Promoting generic drug usage in Japan: correlation between generic drug usage and monthly personal income." Journal of Pharmaceutical Policy and Practice, 2023-02-22 (policy background: 2015 cabinet targets, nonproprietary-name prescribing, patient choice at pharmacy, 80%+ by FY2023 prefecture target in 2021 policy). https://link.springer.com/article/10.1186/s40545-023-00532-5 ↩

5. MHLW. 「安定供給の確保を基本として、後発医薬品を適切に使用していくためのロードマップ及びバイオ後続品の使用促進のための取組方針の策定について」 (press release, 2024-09-30; revised roadmap and targets). https://www.mhlw.go.jp/stf/newpage_43996.html ↩ ↩² ↩³